About PanMed
PanMed is a Healthcare company based in Largo (United States) founded in 1988, and was acquired by Zavation in September 2018. Medical devices for interventional radiology and spine procedures are developed. Its chief executive, as recorded, is Max Nasralla. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its competitors include Nevro, Vertos Medical and Paradigm Spine; 3 of its 3 listed competitors have raised funding.
Company details
PanMed US researches and develops products for interventional radiology and kyphoplasty products. A few products of the company are - balloons for PTA and embolectomy catheters, kyphoplasty balloons and kits for spine vertebral augmentation. The company also offers biliary dilation catheter, esophageal balloon dilatation catheter, cobalt chromium balloon expandable stent, vascular surgery catheters, stent graft balloon catheters, etc. The company claims to manufacture products in compliance with the Council Directive 9342EEC. The companys 13G InterV Kyphoplasty Catheter (Micro) and 11G InterV Kyphoplasty Catheter (Mini-Flex) have been FDA 510(k) cleared (K162453).
Investors in PanMed
PanMed has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Zavation and LongueVue Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
LongueVue Capital is engaged in private equity investments for middle market companies. | 2001 | lvcpartners.com | New Orleans, USA | |
Medical devices for spine surgery are designed, manufactured, and distributed. | 2010 | zavation.com | Flowood, United States |
Investor details for PanMed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PanMed
1 people are tracked at PanMed (1 in leadership).
| Name | Role | Group |
|---|---|---|
Max Nasralla | CEO & President | Leadership |
Complete people profiles for PanMed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PanMed
2 dated milestones of PanMed across 30 years, from founding to its latest funding, stage changes and deals.
- Founded PanMed is founded.
- Exit Acquired by Zavation.
Competitors of PanMed
PanMed has 3 listed competitors in our database, 3 of them funded. They include Nevro, Vertos Medical and Paradigm Spine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nevro.com | 2006 | Menlo Park, United States | $154.1M | 1,215 | Provider of high-frequency spinal cord stimulation implants | |
| vertosmed.com | 2005 | Aliso Viejo, United States | $177.75M | 140 | Minimally invasive treatments for lumbar spinal stenosis are developed. | |
| paradigmspine.com | 2005 | New York, United States | $142.15M | 43 | Stabilization devices for healthcare are manufactured by the company. |
Detailed competitors of PanMed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Orthopedics
3 companies that operate in the same segment as PanMed (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Panmed
Complete news archive for PanMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PanMed
PanMed was founded in 1988.
PanMed is headquartered in Largo, United States. It is registered at Largo, Florida, United States.
Max Nasralla is the CEO of PanMed, as recorded in our data.
PanMed US researches and develops products for interventional radiology and kyphoplasty products. A few products of the company are - balloons for PTA and embolectomy catheters, kyphoplasty balloons and kits for spine vertebral augmentation. The company also offers biliary dilation catheter, esophageal balloon dilatation catheter, cobalt chromium balloon expandable stent, vascular surgery catheters, stent graft balloon catheters, etc. The company claims to manufacture products in compliance with the Council Directive 9342EEC. The companys 13G InterV Kyphoplasty Catheter (Micro) and 11G InterV Kyphoplasty Catheter (Mini-Flex) have been FDA 510(k) cleared (K162453).
PanMed's top competitors include Nevro, Paradigm Spine and Vertos Medical.
PanMed has 2 investors. Key investors include Zavation, and LongueVue Capital.
Yes. PanMed was acquired by Zavation in September 2018.